Segments - Optogenetics Actuators and Sensors Market by Product (Actuators, Channel Rhodopsin, Halo Rhodopsin, Archaerhodopsin, Sensors, Genetically Encoded Calcium Indicators, Voltage-Sensitive Fluorescent Proteins, pH Sensors, Retinal Disorders, and Others), Disease Type (Parkinson’s Disease, Anxiety & Depression, Autism, Schizophrenia, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2024–2032
The global optogenetics actuators and sensors market size was USD 490 Billion in 2023 and is projected to reach USD 560.2 Billion by 2032, expanding at a CAGR of 1.5% during 2024–2032. The market growth is attributed to the increasing adoption of optogenetics technology across various industries and research domains.
Advancing research endeavors and expanding applications across diverse sectors is boosting the optogenetics actuators and sensors market. These sophisticated tools enable precise manipulation and monitoring of neuronal activity, offering unprecedented insights into brain function, neural circuits, and neurological disorders. Researchers utilize optogenetics actuators and sensors to study neural networks, map brain connectivity, investigate psychiatric disorders, and develop targeted therapies for neurological conditions. Furthermore, the increasing number of deaths related to neurological disorders led to the need for advanced technology, including optogenetics actuators and sensors, thereby fueling the market.
According to a report by the Pan American Health Organization, neurological conditions caused 533,172 deaths in 2019. Of these deaths, 40% were in men (213,129) and 60% were in women (320,043).
The use of artificial intelligence is likely to boost the optogenetics actuators and sensors market. Artificial Intelligence is enhancing efficiency, accuracy, and innovation across various stages of research and development. AI-driven image processing techniques enable automated detection and analysis of neuronal activity patterns, facilitating real-time monitoring and interpretation of experimental results. Moreover, AI algorithms optimize experimental design and parameter selection, maximizing the effectiveness of optogenetics protocols and minimizing resource utilization.
Rising burden of neurological and retinal disorders is expected to drive the market. Optogenetics offers approaches for studying and potentially treating these disorders by providing precise control over neuronal activity and gene expression in specific regions of the brain and retina. For instance, according to a November 29, 2023 report by the National Institutes of Health, neurological disorders caused 97.72 million DALYs (disability-adjusted life-year) in 2019, resulting in an age-standardized DALY rate of 1253.56 per 100,000 population. Furthermore, advancements in optogenetics technology, such as the development of novel actuators and sensors with improved performance and specificity, thereby propelling the market.
High costs associated with optogenetics equipment and tools are anticipated to restrain the growth of the optogenetics actuators and sensors market. The initial investment required for optogenetics research, including the purchase of specialized light sources, detectors, and genetically encoded actuators and sensors is high for small healthcare settings. Additionally, maintenance and operational expenses further contribute to the overall cost burden, thereby affecting the market during the forecast period.
Ongoing R&D activities in neuroscience are expected to create immense opportunities for the players competing in the market. Manufacturers are focusing on developing precise tools that manipulate and monitor neuronal activity with high spatiotemporal resolution. Additionally, collaborations between academic institutions, research organizations, and biotechnology companies are creating innovation in the field of optogenetics, thereby boosting market expansion.
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.
Attributes |
Details |
Report Title |
Optogenetics Actuators and Sensors Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2023 |
Historic Data |
2017 -2022 |
Forecast Period |
2024–2032 |
Segmentation |
Product (Actuators, Channel Rhodopsin, Halo Rhodopsin, Archaerhodopsin, Sensors, Genetically Encoded Calcium Indicators, Voltage-Sensitive Fluorescent Proteins, pH Sensors, Retinal Disorders, and Others) and Disease Type (Parkinson’s Disease, Anxiety & Depression, Autism, Schizophrenia, and Others) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
Key Players Covered in the Report |
Addgene; Beacon Therapeutics; Bruker; Circuit Therapeutics, Inc; Danaher; Elliot Scientific Ltd; Gensight Biologics; Merck KGaA; Noldus Information Technology BV ; Prizmatix; Scientifica, A Judges Scientific plc company; Shanghai Laser & Optics Century Co., Ltd; The Jackson Laboratory; Thorlabs, Inc |
Based on product, the optogenetics actuators and sensors market is divided into actuators, channel rhodopsin, halo rhodopsin, archaerhodopsin, sensors, genetically encoded calcium indicators, voltage-sensitive fluorescent proteins, pH sensors, retinal disorders, and others. The genetically encoded calcium indicators segment held the major share of the market in 2023, due to their wide utilization in neuroscience research for monitoring neuronal activity with high spatial and temporal resolution.
GECIs offer several advantages, including compatibility with optogenetics techniques, non-invasiveness, and the ability to visualize calcium dynamics in real time. Moreover, the growing demand for precise tools to study neural networks and neurological disorders further boosts the segment.
The voltage sensitive fluorescent proteins segment is expected to expand at a significant growth rate in the coming years, as they enable researchers to monitor membrane potential changes in neurons with high spatial resolution. VSFPs offer unique advantages, such as optical readouts of neuronal activity and compatibility with optogenetics techniques for precise control of neural circuits. Moreover, the increasing focus on understanding the electrical properties of neurons and synaptic transmission boosts the demand for VSFPs, thereby fueling the market.
On the basis of diseases type, the global market is segregated into Parkinson’s disease, anxiety & depression, autism, schizophrenia, and others. The Parkinson’s diseases segment held largest market share in 2023, due to the growing number of patients suffering from this type of diseases.
Optogenetics is being widely used for studying Parkinson's disease pathology and developing targeted therapies to modulate neural circuits involved in motor control. Moreover, researchers are utilizing optogenetics actuators and sensors to manipulate and monitor neuronal activity in animal models of Parkinson's disease, enabling a deeper understanding of disease mechanisms and potential treatment strategies. These all factors are contributing to boosting the market.
The anxiety & depression segment is anticipated to grow at a substantial CAGR during the forecast period, due to the growing prevalence of mental health disorders worldwide Optogenetics holds immense potential for elucidating the neural circuits underlying anxiety & depression and developing targeted interventions to alleviate symptoms and improve patient outcomes. Moreover, advancements in optogenetics technology, such as the development of novel actuators and sensors with enhanced precision and specificity, further propel the growth of the segment.
In terms of region, the global optogenetics actuators and sensors market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major market share in 2023, due to its robust infrastructure for neuroscience research. United States has leading research institutions, biotechnology companies, and academic centers at the forefront of neuroscience research. Moreover, this region benefits from favorable government initiatives and funding opportunities fostering innovation and technological advancements in optogenetics, thereby boosting the market during the forecast period.
The market in Asia Pacific is projected to grow at a significant pace in the years to come, owing to rapid urbanization and increasing healthcare expenditure. Furthermore, the growing population suffering from neurological disorders in this region further boosts the demand for optogenetics actuators and sensors.
According to a report published by the National Institutes of Health on September 7, 2022, the total number of DALYs (disability-adjusted life years) caused by neurological diseases was 64.4 million in the South-East Asia and 85.0 million in the Western Pacific.
The optogenetics actuators and sensors market has been segmented on the basis of
Key players competing in the global optogenetics actuators and sensors market are Addgene; Beacon Therapeutics; Bruker; Circuit Therapeutics, Inc; Danaher; Elliot Scientific Ltd; Gensight Biologics; Merck KGaA; Noldus Information Technology BV ; Prizmatix; Scientifica, A Judges Scientific plc company; Shanghai Laser & Optics Century Co., Ltd; The Jackson Laboratory; Thorlabs, Inc
These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base worldwide.
On December 6, 2023, Danaher Corporation, a leading global innovator in life sciences and diagnostics, announced acquization of Abcam plc. This acquisition made through a court-sanctioned scheme of arrangement under the UK Companies Act 2006, for a cash price of $24.00 per share. The Scheme became effective on December 6, 2023, resulting Abcam is now an indirect wholly-owned subsidiary of Danaher.